BACKGROUND: A family history of hematopoietic malignancy is associated with an increased risk of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), although the magnitude of the relative risk is unclear. We estimated the association between familial hematopoietic cancer and risk of lymphoma using validated, registry-based family data, and we also investigated whether associations between some environmental exposures and risk of lymphoma vary between individuals with and without such a family history. METHODS: In a population-based case-control study of malignant lymphoma, 1506 case patients and 1229 control subjects were linked to the Swedish Multi-Generation Register and then to the Swedish Cancer Register to ascertain history of cancer in first-degree relatives of patients with malignant lymphoma. Multiple logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations with the risk of lymphoma. RESULTS: A history of hematopoietic malignancy in any first-degree relative was associated with an increased risk of all NHL (OR = 1.8, 95% CI = 1.2 to 2.5), common B-cell NHL subtypes, and HL. Relative risks were generally stronger in association with sibling hematopoietic cancer (OR for all NHL = 3.2, 95% CI = 1.3 to 7.6) than with parental hematopoietic cancer (OR = 1.6, 95% CI = 1.1 to 2.3). A family history of NHL or chronic lymphocytic leukemia (CLL) was associated with an increased risk of several NHL subtypes and HL, whereas familial multiple myeloma was associated with a higher risk of follicular lymphoma. There was no statistically significant heterogeneity in NHL risk associations with environmental factors between individuals with and without familial hematopoietic malignancy. CONCLUSIONS: The increased risk of NHL and HL among individuals with a family history of hematopoietic malignancy was approximately twofold for both lymphoma types. There was no evidence that etiologic associations varied between familial NHL and nonfamilial NHL.
BACKGROUND: A family history of hematopoietic malignancy is associated with an increased risk of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), although the magnitude of the relative risk is unclear. We estimated the association between familial hematopoietic cancer and risk of lymphoma using validated, registry-based family data, and we also investigated whether associations between some environmental exposures and risk of lymphoma vary between individuals with and without such a family history. METHODS: In a population-based case-control study of malignant lymphoma, 1506 case patients and 1229 control subjects were linked to the Swedish Multi-Generation Register and then to the Swedish Cancer Register to ascertain history of cancer in first-degree relatives of patients with malignant lymphoma. Multiple logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations with the risk of lymphoma. RESULTS: A history of hematopoietic malignancy in any first-degree relative was associated with an increased risk of all NHL (OR = 1.8, 95% CI = 1.2 to 2.5), common B-cell NHL subtypes, and HL. Relative risks were generally stronger in association with sibling hematopoietic cancer (OR for all NHL = 3.2, 95% CI = 1.3 to 7.6) than with parental hematopoietic cancer (OR = 1.6, 95% CI = 1.1 to 2.3). A family history of NHL or chronic lymphocytic leukemia (CLL) was associated with an increased risk of several NHL subtypes and HL, whereas familial multiple myeloma was associated with a higher risk of follicular lymphoma. There was no statistically significant heterogeneity in NHL risk associations with environmental factors between individuals with and without familial hematopoietic malignancy. CONCLUSIONS: The increased risk of NHL and HL among individuals with a family history of hematopoietic malignancy was approximately twofold for both lymphoma types. There was no evidence that etiologic associations varied between familial NHL and nonfamilial NHL.
Authors: Sophia S Wang; Susan L Slager; Paul Brennan; Elizabeth A Holly; Silvia De Sanjose; Leslie Bernstein; Paolo Boffetta; James R Cerhan; Marc Maynadie; John J Spinelli; Brian C H Chiu; Pier Luigi Cocco; Fiona Mensah; Yawei Zhang; Alexandra Nieters; Luigino Dal Maso; Paige M Bracci; Adele Seniori Costantini; Paolo Vineis; Richard K Severson; Eve Roman; Wendy Cozen; Dennis Weisenburger; Scott Davis; Silvia Franceschi; Carlo La Vecchia; Lenka Foretova; Nikolaus Becker; Anthony Staines; Martine Vornanen; Tongzhang Zheng; Patricia Hartge Journal: Blood Date: 2006-12-21 Impact factor: 22.113
Authors: M Schenk; M P Purdue; J S Colt; P Hartge; A Blair; P Stewart; J R Cerhan; A J De Roos; W Cozen; R K Severson Journal: Occup Environ Med Date: 2008-09-19 Impact factor: 4.402
Authors: James R Cerhan; Zachary S Fredericksen; Alice H Wang; Thomas M Habermann; Neil E Kay; William R Macon; Julie M Cunningham; Tait D Shanafelt; Stephen M Ansell; Timothy G Call; Thomas E Witzig; Susan L Slager; Mark Liebow Journal: Int J Mol Epidemiol Genet Date: 2011-04-05
Authors: Amy M Linabery; Erik B Erhardt; Michaela R Richardson; Richard F Ambinder; Debra L Friedman; Sally L Glaser; Alain Monnereau; Logan G Spector; Julie A Ross; Seymour Grufferman Journal: Int J Cancer Date: 2015-05-19 Impact factor: 7.396